DDInter1042 DDInter706
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dobutamine
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tagraxofusp
Exenatide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Exenatide may cause a minor interaction that can limit clinical effects when taken with Digoxin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Exenatide may lead to a major life threatening interaction when taken with Bexarotene